Tanvex BioPharma, Inc. (TPE:6541)

Taiwan · Delayed Price · Currency is TWD

31.80

+0.20 (0.63%)

Sep 8, 2026, 1:30 PM CST

Market Cap	8.37B -31.7%
Revenue (ttm)	657.56M +492.4%
Net Income	-1.47B
EPS	-5.59
Shares Out	264.99M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	202,694
Open	32.10
Previous Close	31.60
Day's Range	31.35 - 32.10
52-Week Range	30.80 - 68.00
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About Tanvex BioPharma

Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicines. The company was founded in 2011 and is headquartered in George Town, the Cayman Islands. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Country Cayman Islands

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6541

Full Company Profile

Financial Performance

In 2025, Tanvex BioPharma's revenue was 400.97 million, an increase of 1056.27% compared to the previous year's 34.68 million. Losses were -1.50 billion, 8.59% more than in 2024.

Financial Statements